164 related articles for article (PubMed ID: 33331218)
1. Assessment of Pediatric Chemotherapy-Induced Peripheral Neuropathy Using a New Patient-Reported Outcome Measure: The P-CIN.
Smith EML; Kuisell C; Kanzawa-Lee G; Bridges CM; Cho Y; Swets J; Renbarger JL; Gilchrist LS
J Pediatr Oncol Nurs; 2021; 38(2):131-141. PubMed ID: 33331218
[No Abstract] [Full Text] [Related]
2. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
[TBL] [Abstract][Full Text] [Related]
3. In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials.
Smith EML; Knoerl R; Yang JJ; Kanzawa-Lee G; Lee D; Bridges CM
Cancer Control; 2018; 25(1):1073274818756608. PubMed ID: 29480026
[TBL] [Abstract][Full Text] [Related]
4. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
[TBL] [Abstract][Full Text] [Related]
5. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
Lavoie Smith EM; Barton DL; Qin R; Steen PD; Aaronson NK; Loprinzi CL
Qual Life Res; 2013 Dec; 22(10):2787-99. PubMed ID: 23543373
[TBL] [Abstract][Full Text] [Related]
6. The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers.
Gilchrist LS; Tanner L
Support Care Cancer; 2013 Mar; 21(3):847-56. PubMed ID: 22993026
[TBL] [Abstract][Full Text] [Related]
7. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure.
Lavoie Smith EM; Haupt R; Kelly JP; Lee D; Kanzawa-Lee G; Knoerl R; Bridges C; Alberti P; Prasertsri N; Donohoe C
Oncol Nurs Forum; 2017 Sep; 44(5):580-588. PubMed ID: 28820525
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
[TBL] [Abstract][Full Text] [Related]
9. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
Tofthagen CS; McMillan SC; Kip KE
Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
11. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
[TBL] [Abstract][Full Text] [Related]
12. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vincristine-induced peripheral neuropathy in children with cancer: Turkish validity and reliability study.
Özdemir B; Gerçeker GÖ; Özdemir EZ; Yildirim BG; Ören H; Yiş U; Günay Ç; Thomas GÖ
J Pediatr Nurs; 2023; 72():185-190. PubMed ID: 37076371
[TBL] [Abstract][Full Text] [Related]
16. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
[TBL] [Abstract][Full Text] [Related]
17. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
[TBL] [Abstract][Full Text] [Related]
18. Examination of the psychometric properties of pediatric-modified total neuropathy score in Turkish children with cancer.
Özdemir B; Gerçeker GÖ; Özdemir EZ; Yıldırım BG; Ören H; Yiş U; Günay Ç; Thomas GÖ
J Pediatr Nurs; 2023; 69():31-37. PubMed ID: 36603498
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children.
Gilchrist LS; Marais L; Tanner L
Support Care Cancer; 2014 Feb; 22(2):359-66. PubMed ID: 24072474
[TBL] [Abstract][Full Text] [Related]
20. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums.
Smith EM; Cohen JA; Pett MA; Beck SL
Cancer Nurs; 2010; 33(3):173-83. PubMed ID: 20357656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
